Compounds and compositions as STAT3 degraders and uses thereof
WO2026143124A1PCT designated stage Publication Date: 2026-07-02THE RGT UNIV OF MICHIGAN
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- THE RGT UNIV OF MICHIGAN
- Filing Date
- 2025-12-23
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
The abnormal activation of STAT3 signaling pathways is implicated in various human diseases, particularly in cancer, leading to poor prognosis and tumor progression, and current therapeutic strategies are inadequate for effectively modulating this pathway.
Method used
Development of compounds that degrade STAT3 protein, including specific structures of Formula I, their pharmaceutically acceptable salts, solvates, and stereoisomers, which can be administered to degrade or inhibit STAT3, thereby treating STAT3-mediated diseases.
Benefits of technology
The compounds effectively degrade STAT3, leading to tumor regression and reduced cancer cell proliferation, survival, and immune evasion, providing a therapeutic strategy for treating STAT3-mediated diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025061149_02072026_PF_FP_ABST
Abstract
Compounds of the Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers are provided, as well as their uses for inhibiting and / or degrading certain signal transducer and activator of transcription (STAT) proteins such as STAT3. The compounds may be useful for treatment of cell proliferative disorders such as cancer or other diseases and conditions for which degradation of STAT3 may provide a therapeutic benefit. ST-L-VL (I)
Need to check novelty before this filing date? Find Prior Art